Kristina M. Johnson - 13 Feb 2026 Form 4 Insider Report for Churchill Capital Corp X/Cayman (CCCX)

Role: Director
Signature: /s/ Jason D. Hall, Attorney-in-Fact
Issuer symbol: CCCX
Transactions as of: 13 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 18 Feb 2026, 08:54:01 UTC
Previous filing: 18 Dec 2025
Next filing: 10 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
JOHNSON KRISTINA M	Director	C/O INFLEQTION, INC., 1315 WEST CENTURY DRIVE, SUITE 150, LOUISVILLE	/s/ Jason D. Hall, Attorney-in-Fact	18 Feb 2026	0001116268

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCX	Common Stock	Award		+33,120			33,120	13 Feb 2026	See footnote	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCX	Stock Option (Right to Buy)	Award		+373,458			373,458	13 Feb 2026	Common Stock	373,458	$0.9000	Direct	F1, F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of September 8, 2025, by and among Churchill Capital Corp X, a Delaware corporation now known as Infleqtion, Inc. ("Acquiror"), AH Merger Sub I, Inc., a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub I"), AH Merger Sub II, LLC, a direct, wholly-owned Subsidiary of Acquiror ("Merger Sub II" and together with Merger Sub I, "Merger Subs") and ColdQuanta, Inc. (the "Company") pursuant to which (a) Merger Sub I was merged with and into the Company, and the Company continued as the surviving corporation and immediately thereafter, (b) the Company merged with and into Merger Sub II, and Merger Sub II became the surviving company and continued in existence as a wholly-owned subsidiary of Acquiror (collectively, the "Mergers"). In connection with the Mergers, Acquiror changed its name to Infleqtion, Inc. (the "Issuer").
F2	Represents shares of common stock of the Issuer issued upon conversion of the Company's Series C-1 preferred stock pursuant to the Mergers.
F3	Held directly by Catalyzer Ventures, LP Fund I ("Catalyzer"). Dr. Johnson may be deemed to beneficially own shares held by Catalyzer by virtue of her voting power and investment power over such shares.
F4	The shares vest on a monthly basis beginning on June 1, 2024 with respect to 1/36 of the total number of shares until such time as the option is 100% vested, subject to the continuous service of the Reporting Person as of each such date.
F5	Pursuant to the Mergers, the legacy stock options of the Company were automatically converted into the right to receive stock options of the Issuer with the same terms and conditions.